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Abstract 
 Nigeria is presently suffering from another Lassa fever epidemic. This was confirmed in the statement of the Minister of 
Health of the Federation in which he said, “There has been an upsurge in the reported  cases of Lassa fever since the 
beginning of this year, especially in the Federal Capital Territory and its environs.  
Within two weeks, 12 cases with five deaths due to the disease were recorded. 25 contacts are confirmed by laboratory 
investigations to have been infected, including 4 health staff working in the National Hospital, Abuja.”1   
Lassa fever is an acute viral haemorrhagic fever first described in 1969 in the town of Lassa in Borno state, Nigeria.2 It is 
endemic in West African countries, and causes 300,000 cases annually with 5000 deaths.3 Lassa fever epidemics occur in 
Nigeria, Liberia, Sierra Leone, Guinea and the Central African Republic.4 Lassa virus, the agent of the disease is a 
member of the Arenaviridae family. The virus is pleomorphic with single-stranded and bisegmented RNA genome.3 Its 
primary host is Natal Multimammate Mouse (Mastomys natalensis).  Transmission to man occurs via exposure to the rat 
excrement through respiratory or gastrointestinal tracts5, exposure of broken skin or mucus membrane to infected 
material, direct contact, sexually and transplacentally. 
The prevalence of antibodies to the virus is 8-22%9  in Sierra Leone, 4-55% in Guinea,12 and 21% in Nigeria.13 The 
disease is mild or asymptomatic in 80% of infected people, but 20% have a severe multisystemic disease. Clinical features 
are difficult to differentiate from that of other viral haemorrhagic fevers and common febrile illness such as Malaria, 
Typhoid fever and so on. Definitive diagnosis is by viral isolation, Antigen and Antibody detection and Reverse 
Transcriptase PCR. Treatment is with Ribavirin, an antiviral agent. No vaccine is currently available. Prevention is by 
keeping rats away from homes. 
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INTRODUCTION 
Nigeria is presently suffering from another 
Lassa fever epidemic. The Minister Of Health of 
the country said in a statement on the recent 
Lassa fever outbreak that: “ Since the beginning 
of this year, there has been an upsurge in the 
reported cases of Lassa fever especially in the 
Federal Capital Territory (FCT) and its environs. 
Within the last two weeks, we have recorded 12 
cases with five deaths (41.7% case fatality). 
Much more worrisome is the danger that the 
outbreak poses to health workers. Four health 
staff working in the National Hospital, Abuja 
who were taking care of one of the Lassa fever  
 
cases have also fallen ill and laboratory 
investigations have confirmed they are infected 
with the Lassa virus.” “About 25 contacts in all 
were found to be positive with the Lassa virus 
from laboratory investigations but did not come 
down with the disease” (1). 
  
Lassa fever is an acute viral haemorrhagic fever 
first described in 1969 in the town of Lassa in 
Borno state, Nigeria, located in the Yedseram 
river valley at the south end of Lake Chad (2). 




over a decade earlier but not connected with this 
viral  
 
pathogen. The infection is endemic in West 
African countries, and causes 300,000-500,000 
cases annually with approximately 5000 deaths 
(3). Outbreaks of the diseases occur in Nigeria, 
Liberia, Sierra Leone, Guinea and Central 
African Republic, but it is believed that human 
infections also exist in Democratic Republic of 
Congo, Mali and Senegal (4).  Its primary animal 
host is the Natal Multimammate Mouse 
(Mastomys Natalensis), an animal indigenous to 
most of Sub-Saharan African (5). The virus is 
probably transmitted by the contact with the 
faeces and urine of animals accessing grain 
stores in residential areas (6). 
 
CAUSATIVE AGENT OF LASSA FEVER 
Lassa fever is caused by the Lassa virus, a 
member of the arena viridae;  it is an enveloped, 
single-stranded, bisegmented RNA virus (3).  
The virions exhibit pleomorphic morphology 
when examined by cryoelectron microscopy. 
The surface of the virion envelope is studded 
with glycoprotein projections that consist of 
tetrameric complexes of the viral Glycoprotein 
GP1 and GP2 (6). 
 
The genome of Lassa virus like other arena 
consists of two single-stranded RNA segments 
designated S (small) and L (large). In virions, the 
molar ratio of S to L RNAs is roughly 2:1. The 5’ 
terminus of  
each segment contains a tri-or diphosphate 
group and lacks a cap structure. The S RNA 
segment contains two genes that encode three 
final gene products- the nucleo protein (NP or 
N) and the envelope glycol proteins GP1 and 
GP2 (also termed GP-1 and GP-2, or G1 and G2). 
GP1 and GP2 are first expressed as a precursor 
protein, GPC (or GP-C), which is cleaved post 
translationally (7). The L RNA segment contains 
two genes that encode two genes product, the 
viral polymerase (L protein) and Z protein, a 
small protein of undetermined function (7 ). On 
both segment, the genes are arranged in an 
ambisense orientation. The NP and polymerase 
genes reside at the 3’ end of the S and L RNA 
segment, respectively, and are encoded in the 
conventional negative sense- that is, they are 
expressed through transcription of genome – 
complimentary mRNAs. 
 
The genes located at the 5’ end of the S and L 
RNA segment, GPC and Z, respectively, are 
encoded in mRNA sense but there is no 
evidence that they are translated directly from 
genomic RNA. These genes are expressed 
instead through transcription genomic-sense 
mRNAs from antigenomes, full length 
complimentary copies of genomic RNAs that 
function as replicative intermediates (6).   Lassa 
virus will infect almost every tissue in the 
human body. It starts with the mucosa, intestine, 
lungs, and urinary system, and then progresses 





EPIDEMIOLOGY OF LASSA FEVER 
Vectors: Lassa virus is zoonotic. The natural 
hosts for the virus are multimammate rats 
(Mastomys natalenses), which breed frequently 
throughout west, central, and east Africa8. They 
are probably the most common rodent in 
tropical Africa and are found predominantly in 
rural areas and in dwelling more often in 
surrounding country side (9); members of the 
genus are infected persistently and shed the 
virus in their excreta.    Humans are infected by 
contact with rats or by eating them. Rats found 
in houses of infected people are seropositive for 
the virus ten times more often than those in 
control houses (10).  Virus antibodies occur after 
a febrile illness in twice as many people who eat 
rats as in those who do not, and deafness (an 
effect of Lassa fever) occurs four times more 
frequently (11).  Infection in humans typically 
occurs via exposure to animal excrement 
through the respiratory or gastrointestinal tract. 
Inhalation of tiny particles of infective materials 
(aerosol) is believed to be the most significant 
means of exposure (6).  It is possible to acquire 
the infection through broken skin or mucous 
membranes that are directly exposed to infective 
materials. Transmission from person to person 
has also been established, presenting a challenge 
for health care workers.  Sexual transmission 
and transplacental transmission of the virus 
have also been established (4).  Transmission 
through breast milk has been observed (4). 
 
PREVALENCE/INCIDENCE  
Dissemination of the infection can be 
assessed by prevalence of antibodies to the virus 
in populations. The prevalence of antibodies to 
the virus is 8-52%9 in Sierra Leone, 4-55% in 
Guinea (12), and in Nigeria (13). Seropositivity 
has also been found in the Central African 
Republic Democratic of the Congo, Mali and 
Senegal (14).  Sporadic cases have occurred in 
travellers returning to Britain, the Netherlands, 
and Germany from the endemic areas. 
 
MORBIDITY AND MORTALITY 
Lassa fever affects people of all ages. The disease 
is mild or has no observable symptoms in about 
80% of people infected, but 20% have a severe 
multisystem disease.  Incubation period  is 6-21 
days. The virus is excreted in urine for three to 
nine weeks from infection and in semen for 
three month (14).  Sensorineural hearing deficit 
is a visual of the disease it was found in the 29% 
of confirmed cases compare with none of febrile 
controls in hospital in patients (15). In the 
general population, 81% of those who 
experienced sudden deafness had antibodies to 
Lassa virus as against 19% of matched controls 
(16). There is no apparent relationship between 
the severity of viral illness, initial hearing loss, 
or subsequent recovery(16). 
Presentation of cases used to be highest during 
the dry season (January to March) and lowest 
during the wet season (May to November). 
However, recent data from Kenema, Sierra 
Leone show that admissions were highest 
during the change from the dry to the wet 




Lassa fever was responsible for 10-16% of all 
adult medical admissions in 1987 into hospitals 
studies in Sierra Leone and for about 30% of 
adult deaths (18).  The case fatality rate varied 
from 12% -23% for the period of 1997 -2002 (19).  
During pregnancy, high rate of maternal death 
(29%) and fatal and neonatal loss (87%) have 
been recorded, with 20% of all maternal deaths 
in Sierra Leone being due to Lassa fever (20).  An 
estimate of the case fatality rate in the general 
population is 1-2%, must lower than in 
hospitalized cases, possibly as a consequence of 
differences in severity. 
 
Using the figures for rural populations 
(available from United Nations Development 
Programme) and the epidemiology of the 
disease we estimate that the ‘at risk’ 
seronegative population (in Sierra Leone, 
Guinea, and Nigeria) may be as high as 59 
million, with an annual incidence of illness of 
three million, fatalities up to 67,000 and up to 
three million reinfections (19). 
 
CLINICAL FEATURES OF LASSA FEVER 
Infection with Lassa virus leads to the gradual 
onset of fever and malaise after an incubation 
period of about 10 days (range, 5-21days), as the 
process develops, there is an increase in fever 
and myalagia, with severe prostration. 
Gastrointestinal manifestations such as 
abdominal  
pain, nausea, and vomiting, diarrhoea, or 
constipation are common. Sore throat occurs in 
two thirds of cases and is usually accompanied 
by objective inflammatory or exudative 
pharyngitis. Retrostenal pain and cough are 
frequent, and pleural effusions may develop. 
Bleeding manifestations are seen in less than a 
third of patients but signal an unfavourable 
prognosis. Signs of increase vascular 
permeability such as facial oedema or pleural 
effusion are present in a minority of patient and 
also suggest a poor prognosis. Mortality in 
hospitality patients is 15-20% (6). 
 
A careful case-control study comparing Lassa 
fever to other febrile diseases seen in a West 
African hospital found features significantly 
associated with Lassa fever, including bleeding, 
oedema, exudative pharyngitis, conjunctivitis, 
and pharyngitis, but positive predictive values 
ranged between 0.61 to 0.74 (18).  The same 
study also found vomiting, sore throat, 
tachypnoea, or bleeding to predict a 2.5-fold or 
higher increased risk of death. In spite of the 
relative non-specificity of the clinical findings, 
more than three fourths of patients thought to 
have severe Lassa fever are confirmed through 
viral assays. Lassa fever is a major paediatric 
problem as well (21, 22).  Disease is more 
difficult to diagnose clinically. Occassionally, 
cases of infants developing anasarca have been 
described. 
 
The course of fatal Lassa fever is relentless, with 
progression of signs and symptoms culminating 
in the onset of shock and death.  In  
Survivors symptoms and viremia persist until, 2 
to 3 weeks after onset, there is defervescence 
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accompanied by the disappearance of virus from 
the blood.  Pericarditis may occur in early 
convalescence, particularly in male patients. A 
case of polyserositis and recurrent pericarditis 
with constriction has been reported, which 
suggest that such complications should be 
sought more carefully (23). 
Neurologic disease is not usually a dominant 
clinical manifestation in Lassa fever, but aseptic 
meningitis, encephalitis, global encephalopathy 
with seizures, and more subtle neurologic 
problems are well described (24-26).  Cerebellar 
ataxia in convalescence is an uncommon but 
interesting occurrence. In convalescence, 
deafness is common; this is an important feature 
of Lassa fever, as it provides an important 
diagnostic clue (27).  Late in course of the 
disease or early in convalescence, unilateral or 
bilateral hearing loss was noted in 29% of 
prospectively studied patients (15).  No 
treatment is available and the effects may be 
transitory or often permanent. The auditory 
patterns and clinical course resemble idiopathic 
nerve deafness (16). 
 
The clinical laboratory provides few clues to the 
diagnosis. The leucocytes count can be low, 
normal, or modestly elevated. Platelet counts are 
generally normal but may be modestly 
decreased (28). Albuminuria is common. AST is 
usually at least mildly elevated and the degree 
of elevation, which parallels the viremia, is 
useful predictor of mortality 29. Patients with 
AST values in the hundreds or thousands are at 
considerable risk of dying even with ribavirin 
treatment. Chest radiography may show 
infilterates, pleural effusions, or, more 
commonly, no abnormalities. 
Electrocardiographic findings are often non-
specifically abnormal (30). 
 
Lassa virus also causes unusually high fetal 
mortality. Gravid women have been recognized 
to have an increased risk of death from Lassa 
fever, and prospective studies have shown that 
this is particularly pronounced 30% in the third 
trimester, compared to a 13% mortality in non 
pregnant women20. Fetal loss was 87%, all 
infants infected in the last trimester died in-
utero or during the neonatal period. Viremia, 
which is correlated with the risk of dying in 
Lassa fever patients, was higher in pregnant 
than non pregnant women. High concentrations 
of virus were found in fetal tissue as well as 
placenta (31).  the biologic basis for these 
findings is unknown, but it seems likely that, 
once infected, the immature fetus is unable to 
mount an effective T-cell response to control the 
virus infection, maternal T cells would not be 
able to attack the placental infection because of 
the lack of MHC class I or II antigen expression 
on placental cells (32).  Thus, the fetus and its 
supporting tissues would be a source of high 
level virus production. 
LABORATORY DIAGNOSIS  
There are a range of laboratory investigations 
that are performed to diagnose the disease and 
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assess its course and complications. Lassa virus 
is easily isolated from the blood or serum during 
the febrile phase of the disease up to 14 or more 
days after onset, even after the appearance of 
IFA antibody. Virus can also be detected in 
necropsy tissues (33, 24). Vero cell cultures 
examined by fluorescent antigbody allow a 
diagnosis in 5 to 7 days or sooner. Lassa virus 
antigen can be detected by ELISA capture in 
serum within 4 hours of beginning testing and 
as it becomes negative, Igm antibodies appear 
(35).  Antigen detection by ELISA is robust and 
reliable in rapidly fatal cases, even if the 
specimens are not handled properly for virus 
isolation (35).  ELISA test for antigen and IgM 
antibodies give 88% sensitivity and 90% 
specificity for the presence of the infection (4).  
Reverse transcriptase (RT-PCR) is also a 
sensitive test for virus RNA, being positive in 
the blood of 23 of 29 patients are admission and 
29 of 29 patients by the third day of 
hospitalization (36, 37). 
Antibody can be detected by CF, IFA, or ELISA. 
IFA using lassa-infected vero cells as substrate is 
widely used (38)  interpretation is subjective and 
discrepancies between laboratories are common 
IFA IgG seroreversion has been reported and 
thought to represent loss of antibody by 
previously sero-positive individuals (9).  Lassa 
IgG and IgM can also be detected by ELISA (35, 
39, 40).  ELISA IgM titres appear earlier and 
persist longer than IFA IgM titres. IgG ELISA 
antibody persists for long period, whereas IFA 
antibody appears to wane below detectable 
limits within several years (6). 
Other effects of illness include lymphocytopenia 
and a moderate thrombocytopenia, which are 
maximal 10-11 days after the onset of symptoms 
(19)  the thrombocytopenia is associated with a 
serum inhibitor and with the occurrence of 
haemorrhage, depression of platelet 
aggregation, and the severity of Lassa fever (19).   
TREATMENT  
All persons suspected of Lassa fever infection 
should be admitted to isolation facilities and 
their body fluids and excrete properly disposed. 
ANTIVIRAL DRUGS  
Although several compounds have shown in 
vitro efficacy, only the guanosine analogue 
ribavirin has had practical application. The drug 
is efficacious in lassa fever and is the therapeutic 
agent of choice in the disease (6).  Early and 
aggressive treatment of Lassa fever using 
ribavirin was pioneered by Joe Mccormick in 
1979.  After extensive testing, it was determined 
that early administration is critical to success. 
Additionally, 
ribavirin is almost twice as effective when given 
intravenously as when taken by mouth (41).  
ribavirin is a prodrug which appears to interfere 
with viral replication by inhibiting RNA 
dependent nucleic acid synthesis, although the 
precise mechanism of action is disputed (42).  
the drug is relatively inexpensive, but the cost of 
the drug is still very high for many of those in 
poverty stricken west African states. 
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When Lassa fever infects pregnant women late 
in their third trimester, it is necessary to abort 
the pregnancy for the mother to have a good 
change of survival (20).  This is because the virus 
has an affinity for the placenta and other highly 
vascular tissues. The fetus has only one in ten 
chance of survival no matter what course of 
action is taken, hence focus is always on saving 
the life of the mother (19).  Following abortion, 
women should receive the same treatment as 
other Lassa fever patients. 
Siga Technologies is developing an antiviral 
drug that has been shown to be effective in 
treating experimentally infected pigs. In a study 
conducted at the U.S Army research institute of 
infections. Disease (USAMRIDD), treatment 
with ST-193 once a day for 14 days resulted in 
significant reduction in mortality (71% of the 
animals survived at the low dose), whereas all 
untreated animals and those treated with 
ribavirin died within 20 days of the infection (4).  
Intravenous interferon therapy has also been 
used in the management of Lassa fever infection 
(4). 
SUPPORTIVE THERAPY  
Supportive therapy is important in the 
management of patient with lassa fever (43, 44).  
Avoidance of travel and general trauma, gentle 
sedation and pain relief with conservative does 
of opiates, the usual precautions of such patients 
with bleeding diatheses (such as avoiding 
intramuscular injections and acetylsalicylic 
acid), and careful maintenance of hydration are 
indicated. Bleeding should be managed by 
platelet transfusions and factor replacement as 
indicated by clinical judgment and laboratory 
studies.  
Management of shock is difficult. Vigorous 
infusion of crystalloid carries a high risk of 
pulmonary edema. Cautious administration of 
fluids and early use of pressors is indicated, but 
careful monitoring is important.  
CONTAINMENT  
The most dangerous exposure is parenteral and 
must be avoided through staff training. Thus, 
patients with these lassa fever should be treated 
in mask, gown, and glove isolation. Protection to 
care givers and other patients should been 
enhanced by the addition of reparatory 
protection against small-particle aerosol (43, 45, 
46).  Close personal contacts should be 
monitored for fever for a period of 3 weeks. The 
patient may continue to excrete virus in urine or 
semen for weeks after recovery, so body fluids 
should be monitored for infectivity before the 
patient is released, meanwhile, a program of 
counselling emphasizing addition of 
disinfectant to toilets before use and protection 
of sexual partners should be followed. Special 
precautions are indicated when blood and other 
body fluids are handled in the clinical 
laboratory 
PASSIVE ANTIBODY  
Lassa virus infections are more difficult 
prospects for antibody therapy than other 
arenaviruses, because the volumes of plasma 
needed based on animal studies are large: 
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experimental studies of IgG for intravenous 
administration indicate the this could be a useful 
means of treatment only if selected, highly 
active preparation were available (48, 49). The 
future of antibody therapy in any of this disease 
lies in development of standardized monoclonal 
antibody preparations of proven efficacy (50, 
51). 
PREVENTION AND CONTROL  
Of all the arenaviridae, the lassa fever virus has 
the greatest public health implication and 
control of the mastomys rodent population is 
impractical, so measures are limited to keeping 
rodent out of homes and food supplies, as well 
as maintaining effective personal hygiene.  
Gloves, face masks, laboratory coats, and 
goggles are advised while in contact with an 
infected person. 
Vaccine against Lassa fever is currently 
unavailable, though development is underway. 
The Mozambique virus closely resembles Lassa 
fever virus but lacks its deadly effects. This virus 
is being considered for possible use as vaccine.  
Researchers at the USAMRIID facility have a 
promising vaccine against Lassa virus based on 
recombination vesicular stomatitis virus vectors 
expressing the Lassa virus glycoprotein. After a 
single intramuscular injection, test primates 
have survived lethal changes, while showing no 
clinical symptoms (53). 
CONCLUSION  
Of  all the Arenavirus diseases, Lassa fever has 
the greatest health impact and prospect for its 
prevention through rodent control is least. No 
vaccine against the disease is currently available. 
The development of vaccines for Lassa fever 
carries several inherent problems. Clinically, 
Lassa fever infections are difficult to distinguish 
from other viral hemorrhagic fever and from 
more common febrile illness such as malaria, 
typhoid fever, shigellosis, leptospirosis, 
rickettsial disease and relapsing fever. Clinical 
laboratory provides little or no clue. RT-PCR 
tests which provide definitive diagnosis are not 
readily available in West African countries. 
Where, it is available it is too expensive and out 
of reach of the poor people living the endemic 
areas. When the diagnosis is made, cost 
Ribavirin and of barrier/isolated care in 
unaffordable. Furthermore, Lassa virus also 
causes usually high fetal mortality. Gravid 
women have been recognized to have an 
increase increased risk of death from Lassa 
fever, particularly pronounced in third 
trimester. All infants infected in the last 
trimester died in utero or during the neonatal 
period. The disease is thus contributing in no 
small way to the high material, neonatal, infants 
and under five mortality rates in West Africa. 
Failure to effectively control the disease makes 
the attainment of the millennium development 
goals of reducing maternal and infant mortality 
rates impossible. 
The disease also has the potential of being used 
as biological weapon. It therefore constitutes an 





1. Chukwuma Muanya, “Minister warns 
health workers of Lassa fever risk”; The 
guardian. Guardian Newspapers 
limited, Lagos, Nigeria. Vol 26, No. 
11,030. Monday, March 9, 2009.  80  
2. Frame JD, Baldwin JM, Gocke DJ, Troup 
JM. “Lassa fever, a new virus disease of 
man from West Africa. I. clinical 
description and pathological findings. 
Am J. trop med. Hyg. 19 (4): 670-6  
3. Ogbu O, Ajuluchukwu E, Uneke CJ.  
‘Lassa fever in West African sub-region: 
an overview.’ Journal of vector borne 
disease 2007;44(1):1-11 
4. Lassa fever – Wikipedia, the free 
encyclopeida, 2009 
5. Werner Dietrich, editor. Biological 
resources and migration. springer. 2004 
pp 363  
6. Micheal J. Buchmeier, Michael D. Bowen 
and Clarence J. Peters In: Bernard N. 
Fields et al (eds); Fields-Virology; 
Lippincott Williams & Wilkins 
Publishers4th ed. 2001. pp 1635-1668 
7. Buchmeier MJ, Southern PJ, Parekh BS 
et al. Site-specific antibodies define a 
cleavage site conserved among 
arenavirus GP-C glycoproteins. J. virol. 
1987; 61:8982-8985.  
8. Healing T, Gopal R. Report on an 
assessment visit to Sierra Leone, April 
12th – 30th 2001. London: Merlin, 2001.   
9. McCormick JB, Webb PA, Krebs JW 
Johnson KM smith ES. A prospective 
study of the epidemiology and ecology 
of Lassa fever. J infect dis 1987; 155: 437-
444 
10. Keenlyside RA, McCormick JB, Webb 
PA, Smith E, Elliott L, Johnson KM. 
Case control study of mastomys 
natalensis and humans in Lassa virus 
infected households in Sierra Leone. Am 
J Trop Med Hyg 1983; 32: 829-37 
11. Ter Meulen J, Lukashevich I, Sidibe K, 
Inapogui A, Marx M, Dorlemann A, et 
al. Hunting of peridomestic rodents and 
consumption of their meat as possible 
risk factors for rodent to human 
transmission of Lassa virus in the 
republic of Guinea. Am J Trop Med Hyg 
1996; 55: 661-6  
12. Lukashevich LS, Clegg JC, Sidibe K. 
Lassa virus activity in Guinea: 
distribution of human antiviral antibody 
defined using enzyme-linked 
immunosorbent assay with recombinant 
antigen. J Med Virol 1993; 40:210-7  
13. Tomori O, Fabiyi A, Sorungbe, Smith A, 
McCormick J.B. Viral haemorrhagic 
fever antibodies in Nigeria populations. 
Am J Trop Med Hgy 1988; 38:407-10  
14. World Health Organization. WHO 
Lassa fever fact sheet No 179. Geneva: 
WHO, 2000  
15. Cummins D, McCormick JB, Bennett D, 
Samba JA, Farrar B, Machin SJ et al. 
153 
 
Acute sensorineural deafness in Lassa 
fever .JAMA 1990; 264:2093-6  
16. Liao BS, Byl FM, Adour KK. 
Audiometric comparison of Lassa fever 
hearing loss and idiopathic sudden 
hearing loss; evidence of viral cause . 
Otolaryngol Head Neck Surg 1992; 
106:226-9 
17. Wilson M. Infectious disease: an 
ecological perspective. BMJ 1995; 311: 
1681-4  
18. McCormick JB, King IJ, Webb PA, 
Johnson KM, O’sullivian R, Smith ES et 
al. A case control study of the clinical 
diagnosis and course of Lassa fever. J 
infect Dis 1987; 155:445-55.  
19. J Kay Richmond and Deborah J Baglole. 
Lassa fever epidemiology, clinical 
features, and social consequences. BMJ 
2003; 327 (7426): 1271-1275. 
20. Price ME, Fisher-Hoch SP, Craven RB, 
McCormick JB. A prospectively study of 
maternal and fetal outcome in acute 
Lassa fever infection during pregnancy. 
BMJ 1988; 297: 584-7  
21. Smadel JE, Green RM, Paltauf RM, 
Gonzales TA. Lymphocytic 
choriomeningitis: Two human fatalities 
following an unusual febrile illness. Pro 
Soc Exp Boil Med 1942; 49: 683.  
22. Smee DF, Gibbertt J, Leonhadt JA, et al 
Treatment of lethal pichinde virus 
infections in weanling LVG/Lak 
hamster with ribavirin, ribamide, 
selenazofurin, and ampligen. Antiviral 
res 1993; 20:57-70. 
23. Hirabayashi Y, Oka S, Goto H et al, an 
imported case of Lassa fever with late 
appearance of polyserositis. J Infect Dis.  
1988, 158: 872-875. 
24. Cummins D, Bennett D, Fisher-Hoch SP, 
et al. Lassa fever encephalopathy: 
clinical and laboratory findings. J trop 
med hyg 1992; 95:197-201. 
25. Smith AL, Paturzo FX, Garden EP et al 
Two epizootics of lymphocytic 
choriomeningitis virus occuring in 
laboratory mice despite intensive 
monitory programs. Can J comp med 1984 
48:335-337. 
26. Solbrig MV. Lassa virus and central 
nervous system disease. In: Salvato MS, 
ed. The Arenaviridae. New York: 
Plenum press, 1993: 325-330.  
27. Frame JD. Surveillance of Lassa fever in 
missionaries stationed in West African. 
Bull world health organ 1975; 52:593-598 . 
28. Fisher-Hoch S, McCormick JB, Sasso D, 
Craven RB. Haematologic dysfunction 
in Lassa fever J med viral. 1988; 26: 127-
135  
29. Johnson KM, McCormick JB, Webb PA, 
et al Clinical virology of Lassa fever in 
hospitalized patients. J infect dis .1987; 
155:456`-464 
30. Cummins D, Bennett D, Fisher-Hoch SP, 
et al. Electrocardiographic abnormalities 




31. Walker DH, McCormick JB, Johnson 
KM, et al. Pathologic and virologic 
study of Lassa fever in man. Am J Pathol 
1982; 107: 349-356. 
32. Hunt JS, Orr HT. HLA and maternal 
fetal recognition. FASEB J    
     1992; 6: 2344-2348 
33. Frame JD, Jahrling PB, Yalley –Ogunro 
JE, Monson MH Endemic Lassa fever in 
Liberia II. Serological and virological 
findings in hospital patients. Trans R Soc 
Trop Med Hyg 1984; 78:656-660.  
34. Johnson KM, McCormick JB, Webb PA. 
Clinical virology of Lassa fever in 
hospitalized patients. J infect dis. 1987; 
155:456-464. 
35. Bausch DG, Rollin PE, Demby AH. 
Diagnosis and clinical virology of Lassa 
fever as evaluated by enzyme-linked 
immunosorbent assay, indirect 
fluorescent antibody test, and virus 
isolation. J clin Microbiol 2000;38:2670-
2677 
36. Demby AH, Chamberlain J, Brown DW, 
Clegg CS. Early diagnosis of Lassa fever 
by reverse transcription PCR. J Clin 
microbiol .1994; 32:2898-2903. 
37. Trappier SG, Conaty AL, Farrar BB et al. 
Evaluation of the polymerase chain 
reaction for diagnosis of Lassa virus 
infection Am J trop Med Hyg .1993; 
49:214-221  
38. Wulff H, Lange JV. Indirect 
immunofluorescence for the diagnosis 
of Lassa fever infection. Bull World 
Health Organ 1975; 52: 429 – 436.   
39. Jahrling PB, Niklasson BS, McCormick 
JB. Early diagnosis of human Lassa 
fever by ELISA detection of antigen and 
antibody. Lancet 1985, 1:250-252. 
40. Niklasson BS, Jahrling PB, Peters CJ. 
Detection of Lassa virus antigens and 
Lassa virus-specific immunoglobulin G 
and M by enzyme-linked 
immunosorbent assay. J Clin Microbiol      
1984;20:239-24. 
41. Fisher-Hoch SP, McCormick JB. “Lassa 
fever vaccine.” Expert review of vaccines. 
2004;  3 (2): 189-97. 
42. Crotty S, Cameron C, Andino R. 
“Ribavirin’s antiviral mechanism of 
action: lethal mutagenesis?” J mol Med. 
2002; 80 (2) 86-96. 
43. Peters CJ, Johnson ED, McKee JKT. 
Filoriviruses and management of viral 
haemorrhagic fevers. In Belshe R, ed. 
Textbook of Human Virology, 2nd ed. St. 
Louis, MO: Mosby year Book, 1991: 699-
712 
44. Peters CJ, Shelokov A. Viral 
haemorrhagic fever. In: Kass EH, Platt 
R, ed. Current therapy in infectious disease, 
vol 3. Toronto: BC Decker, 1990:335-360.  
45. Bannister BA. Stringent precautions are 
advisable when caring for patients with 
viral haemorrhagic fevers. Rev med virol 
1993: 3:3-6.  
46. Fisher-Hoch SP stringent precautions 
are not advisable when caring for 
155 
 
patient with viral haemorrhagic fevers. 
Rev Med virol 1993; 3: 7-13. 
47. Elliott LH, McCormick JB, Johnson KM. 
Inactivation of Lassa, Marburg and 
Ebola viruses by gamma irradiation. J 
clin microbiol 1982; 16: 704-708.  
48. Jahrling PB, Peters CJ. Passive antibody 
therapy of Lassa fever in cynomolgus 
monkeys: Importance of neutralizing 
antibody and lassa virus strain infect 
immune 1984 44: 528-533.  
49. Jahrling PB, Peters CJ, Stephen EI. 
Enhanced treatment of lassa fever by 
immune plasma combined with 
ribavirin in cynomolgus monkeys. J. 










50. Ruo Sl, Mitchell SW, Kiley MP et al. 
Antigenic relatedness between 
arenaviruses defined at the epitope level 
by monoclonal antibodies. J. Gen virol; 
1991;72: 549-555. 
51. Sanchez A, Pifat DY, Kenyon RH et al. 
Junin virus monoclonal antibodies: 
Characterization and cross-reactivity 
with other arenaviruses. J Gen virol 1989; 
70:1125-1132. 
52. Preston, Richard. The demon in the 
freezer, Random House. Inc. 2002. 
53. Geisbert TW, Jones S, Fritz EA, et al. 
Development of a new vaccine for the 
prevention of Lassa fever. PLoS Med. 
















Visit our website:  http//www.ajol.info/journals/ajcem 
 
 
 
 
 
